智通财经APP讯，中国生物科技服务(08037)发布公告，预计2025年中期期间公司拥有人应占亏损将不多于3300万港元，较2024年同期公司拥有人应占亏损7991.7万港元减少约59%。该显著经营表现改善的主要原因是公司成功实施成本控制措施，导致毛利率上升及行政开支减少，以及就2024年发生的暴雨对海南建筑工地造成的损害作出保险申索而获得赔偿收入约1400万港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.